BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 24, 2024
See today's BioWorld
Home
» Home and hospital: Merck-Ridgeback halt and advance COVID-19 study for different patient groups
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Home and hospital: Merck-Ridgeback halt and advance COVID-19 study for different patient groups
April 15, 2021
By
Lee Landenberger
No Comments
Merck & Co. Inc. has shut down two COVID-19 therapy development studies while moving another into a phase III trial.
BioWorld
Clinical
Coronavirus
